| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 602 | 201 | 116 | 399 | 65 | 673 | 258 | 188 | 120 | 734 |
| Gross Profit/Loss - EUR | -602 | -201 | -116 | -399 | -65 | -673 | -258 | -188 | -120 | -734 |
| Net Profit/Loss - EUR | -602 | -201 | -116 | -399 | -65 | -673 | -258 | -188 | -120 | -734 |
| Employees | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Check the financial reports for the company - P.m.c. (Pharmaceutical Management Company) S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 83 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 144 | 90 | 82 | 44 | 284 | 43 | 0 | 0 | 0 | 997 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 45 | 45 | 44 | 43 | 274 | 42 | 0 | 0 | 0 | 0 |
| Cash | 99 | 45 | 38 | 1 | 9 | 1 | 0 | 0 | 0 | 997 |
| Shareholders Funds | -2.189 | -2.367 | -2.444 | -2.798 | -2.809 | -3.429 | -3.611 | -3.810 | -3.919 | -3.666 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 1.005 |
| Debts | 2.415 | 2.457 | 2.526 | 2.842 | 3.093 | 3.471 | 3.611 | 3.810 | 3.919 | 4.663 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8569 - 8569" | |||||||||
| CAEN Financial Year |
8560
|
|||||||||
Comments - P.m.c. (Pharmaceutical Management Company) S.r.l.